NCT00041119
Clinical Trial Information
Trial Number: NCT00041119 (ClinicalTrials.gov)
Disease Type:
- Breast Neoplasm - Breast Cancer (Invasive)
Trial Title:
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Study ID:
CALGB-40101
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00041119-D4 | This dataset is one of 2 datasets associated with PubMed ID 24934787. This dataset contains data on toxicity reported during treatment. |
| NCT00041119-D3 | This dataset is one of 2 datasets associated with PubMed ID 24934787. This dataset contains de-identified patient-level information. The information includes baseline characteristics, eligibility, and data for the comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer. |
| NCT00041119-D2 | This dataset is one of 2 datasets associated with PubMed ID 22826271. This dataset contains data on toxicity reported during treatment. |
| NCT00041119-D1 | The NCT00041119_D1_(FactorA_Patients) dataset is one of 2 datasets associated with PubMed ID 22826271. This dataset contains de-identified patient-level information. The information includes baseline characteristics, eligibility, and endpoint data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®